Desferal
(Deferoxamine)ApprovedSmall molecule
Jazz PharmaceuticalsDeferoxamine is used to treat iron overload in the body, which can occur from repeated blood transfusions or certain blood disorders. It works by binding to excess iron so the body can eliminate it.[2] Desferal is currently approved and in use across 13 indications[4].[1]
Desferal is one of 303 small molecule programs targeting Subarachnoid Hemorrhage. It is currently in Approved.
13
Indications
29
Total Trials
6
Active Trials
302
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Desferal
Jazz PharmaceuticalsApproved
Adenocard
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sickle Cell Disease3 trials
Thalassemia3 trials
Subarachnoid Hemorrhage2 trials
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Recruiting·—·Phase 2·NCT04566991·120 enrolled
COVID-192 trials
Intracerebral Hemorrhage2 trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Terminated·—·Phase 2·NCT01662895·42 enrolled
Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage
Unknown status·—·Phase 1/2·NCT02367248·180 enrolled
17 more indications
Acute Kidney Injury1 trial
Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
Active, not recruiting·—·Phase 2·NCT04633889·320 enrolled
Iron Overload1 trial
Hemochromatosis1 trial
Combination Therapy1 trial
Blood Transfusion1 trial
Allogeneic Stem Cell Transplantation1 trial
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
Terminated·—·N/A·NCT00658411·5 enrolled
Pilot Study1 trial
Pilot Study for Patients With Poor Response to Deferasirox
Completed·—·Phase 4·NCT00749515·15 enrolled
Wound Healing1 trial
Ischemic stroke1 trial
Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke
Completed·—··NCT05748587·48 enrolled
Oxidative Stress1 trial
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
Completed·—·Phase 2/3·NCT04292314·350 enrolled
Safety and Efficacy1 trial
Red Blood Cell Transfusions1 trial
Leptomeningeal Metastases1 trial
Regulatory
FDA Approval Timeline[5]
May 25, 2000
DESFERAL
NDA NDA016267
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Desferal drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Deferoxamine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company